Use of docetaxel (Taxotere®) in patients with paclitaxel (Taxol®) hypersensitivity

被引：32

作者：

Moon, C ^{[1
]}

Verschraegen, CF ^{[1
]}

Bevers, M ^{[1
]}

Freedman, R ^{[1
]}

Kudelka, AP ^{[1
]}

Kavanagh, JJ ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Internal Med Specialities, Sect Gynecol & Med Therapeut, Houston, TX 77030 USA

来源：

ANTI-CANCER DRUGS | 2000年 / 11卷 / 07期

关键词：

allergic reactions; ovarian neoplasms; taxane;

D O I：

10.1097/00001813-200008000-00007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Anaphylaxis or significant hypersensitivity reaction is one of the most catastrophic potential complications of chemotherapy. There is a 2-5% risk of hypersensitivity with paclitaxel, a commonly used chemotherapeutic agent for various cancers. Three patients, who developed hypersensitivity to paclitaxel infusion, received docetaxel without allergic reactions. Docetaxel may therefore be an alternative treatment for patients with paclitaxel hypersensitivity. [(C) 2000 Lippincott Williams & Wilkins].

引用

页码：565 / 568

页数：4

共 50 条

[1] The immunophannacology of paclitaxel (Taxol®) docetaxel (Taxotere®), and related agents
Fitzpatrick, FA
Wheeler, R
INTERNATIONAL IMMUNOPHARMACOLOGY, 2003, 3 (13-14) : 1699 - 1714
[2] THE TAXOIDS - PACLITAXEL (TAXOL(R)) AND DOCETAXEL (TAXOTERE(R))
PAZDUR, R
KUDELKA, AP
KAVANAGH, JJ
COHEN, PR
RABER, MN
CANCER TREATMENT REVIEWS, 1993, 19 (04) : 351 - 386
[3] Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere)
Grant, DS
Williams, TL
Zahaczewsky, M
Dicker, AP
INTERNATIONAL JOURNAL OF CANCER, 2003, 104 (01) : 121 - 129
[4] Managing the neurotoxicity of paclitaxel (Taxol®) and docetaxel (Taxotere®) with neurotrophic factors
Apfel, SC
CANCER INVESTIGATION, 2000, 18 (06) : 564 - 573
[5] PACLITAXEL (TAXOL(TM)) AND DOCETAXEL (TAXOTERE(TM)) - NOT SIMPLY 2 OF A KIND
VERWEIJ, J
CLAVEL, M
CHEVALIER, B
ANNALS OF ONCOLOGY, 1994, 5 (06) : 495 - 505
[6] Chemoenzymatic synthesis of the C-13 side chain of paclitaxel (Taxol) and docetaxel (Taxotere)
Hamamoto, H
Mamedov, VA
Kitamoto, M
Hayashi, N
Tsuboi, S
TETRAHEDRON-ASYMMETRY, 2000, 11 (22) : 4485 - 4497
[7] PACLITAXEL (TAXOL) AND DOCETAXEL (TAXOTERE) - ACTIVE CHEMOTHERAPEUTIC-AGENTS IN LUNG-CANCER
FRANCIS, PA
KRIS, MG
RIGAS, JR
GRANT, SC
MILLER, VA
LUNG CANCER, 1995, 12 : S163 - S172
[8] PACLITAXEL (TAXOL(R)) AND DOCETAXEL (TAXOTERE(R)) AS SINGLE AGENTS - RESULTS OF PHASE-II TRIALS
FUMOLEAU, P
PERROCHEAU, G
MAUGARDLOUBOUTIN, C
LEMEVEL, B
BULLETIN DU CANCER, 1995, 82 (08) : 629 - 636
[9] Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells
Hennequin, C
Giocanti, N
Favaudon, V
CANCER RESEARCH, 1996, 56 (08) : 1842 - 1850
[10] Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere)
Wang, GS
Yang, KY
Perng, RP
BRITISH JOURNAL OF CANCER, 2001, 85 (09) : 1247 - 1250

← 1 2 3 4 5 →